TY - JOUR
T1 - Independent diagnostic and post-treatment prognostic models for prostate cancer demonstrate significant correlation with disease progression end points
AU - Graversen, Joseph A.
AU - Suh, Lara K.
AU - Mues, Adam C.
AU - Korets, Ruslan
AU - Donovan, Michael J.
AU - Khan, Faisal M.
AU - Liu, Qiuhua
AU - Landman, Jaime
AU - Gupta, Mantu
AU - McKiernan, James M.
AU - Badani, Ketan K.
PY - 2012/5/1
Y1 - 2012/5/1
N2 - Background and Purpose: A major advance in the standard practice of tissue-based pathology is the new discipline of systems pathology (SP) that uses computational modeling to combine clinical, pathologic, and molecular measurements to predict biologic activity. Recently, a SP-based prostate cancer (PCa) predictive model for both preoperative (Px+) and postoperative (Px) prostatectomy has been developed. The purpose of this study is to calculate the percent agreement and the concordance between the Px+ and Px end points. Patients and Methods: Fifty-three patients underwent robot-assisted prostatectomy for PCa, and had Px+ and Px testing performed. Data were collected on Px+ end points and Px end points along with pathologic specimen results. The percent agreement and the degree of correlation between the Px+ and Px end points were then calculated. Results: The percent agreement (PA) between Px+ end points and Px end points ranged from 77% to 87%. The PA between a high Px+ favorable pathology (FP) classification and dominant Gleason score ≤3 and Gleason sum ≤6 was 71.7% and 37.4%, respectively. On univariate analysis, Px+ disease progression (DP) score significantly correlated with Px prostate-specific antigen recurrence (PSAR) score (P<0.001), while Px+ DP probability significantly correlated with PxPSAR probability (P<0.001). Px+ FP probability significantly correlated with postprostatectomy dominant Gleason grade ≤3 (P<0.001) and Gleason sum (P<0.001). Conclusion: The PA between Px+ and Px testing end points for radical prostatectomy patients was very good. Furthermore, there was a direct correlation between most Px+ and Px end points. While the Px+FP classification and Gleason sum demonstrated a poor PA, Px+FP score still maintained a direct correlation to prostatectomy Gleason sum.
AB - Background and Purpose: A major advance in the standard practice of tissue-based pathology is the new discipline of systems pathology (SP) that uses computational modeling to combine clinical, pathologic, and molecular measurements to predict biologic activity. Recently, a SP-based prostate cancer (PCa) predictive model for both preoperative (Px+) and postoperative (Px) prostatectomy has been developed. The purpose of this study is to calculate the percent agreement and the concordance between the Px+ and Px end points. Patients and Methods: Fifty-three patients underwent robot-assisted prostatectomy for PCa, and had Px+ and Px testing performed. Data were collected on Px+ end points and Px end points along with pathologic specimen results. The percent agreement and the degree of correlation between the Px+ and Px end points were then calculated. Results: The percent agreement (PA) between Px+ end points and Px end points ranged from 77% to 87%. The PA between a high Px+ favorable pathology (FP) classification and dominant Gleason score ≤3 and Gleason sum ≤6 was 71.7% and 37.4%, respectively. On univariate analysis, Px+ disease progression (DP) score significantly correlated with Px prostate-specific antigen recurrence (PSAR) score (P<0.001), while Px+ DP probability significantly correlated with PxPSAR probability (P<0.001). Px+ FP probability significantly correlated with postprostatectomy dominant Gleason grade ≤3 (P<0.001) and Gleason sum (P<0.001). Conclusion: The PA between Px+ and Px testing end points for radical prostatectomy patients was very good. Furthermore, there was a direct correlation between most Px+ and Px end points. While the Px+FP classification and Gleason sum demonstrated a poor PA, Px+FP score still maintained a direct correlation to prostatectomy Gleason sum.
UR - http://www.scopus.com/inward/record.url?scp=84860456174&partnerID=8YFLogxK
U2 - 10.1089/end.2011.0192
DO - 10.1089/end.2011.0192
M3 - Review article
C2 - 21942796
AN - SCOPUS:84860456174
SN - 0892-7790
VL - 26
SP - 451
EP - 456
JO - Journal of Endourology
JF - Journal of Endourology
IS - 5
ER -